TXMD · TherapeuticsMD, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements.”View the 10-Q filed Aug 11, 2026
Key customers — 100% of revenue (the three and six months ended June 30, 2026)
“For the three and six months ended June 30, 2026, 100% of license revenue related to Mayne Pharma, Theramex and Knight.”
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-08-11 |
TherapeuticsMD Announces Second Quarter 2026 Financial Results
BOCA RATON, Fla. --(BUSINESS WIRE)--Aug. 11, 2026-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2026. |
| 2026-05-12 |
TherapeuticsMD Announces First Quarter 2026 Financial Results
BOCA RATON, Fla. --(BUSINESS WIRE)--May 12, 2026-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2026. |
| 2026-03-30 |
TherapeuticsMD Announces Full Year 2025 Financial Results
BOCA RATON, Fla. --(BUSINESS WIRE)--Mar. 30, 2026-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025. |
| 2025-11-12 |
TherapeuticsMD Announces Third Quarter 2025 Financial Results
BOCA RATON, Fla. --(BUSINESS WIRE)--Nov. 12, 2025-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2025 . |
| 2025-08-12 |
TherapeuticsMD Announces Second Quarter 2025 Financial Results
BOCA RATON, Fla. --(BUSINESS WIRE)--Aug. 12, 2025-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2025 . |
| 2025-05-13 |
TherapeuticsMD Announces First Quarter 2025 Financial Results
BOCA RATON, Fla. --(BUSINESS WIRE)--May 13, 2025-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2025 . |
| 2025-03-27 |
TherapeuticsMD Announces Full Year 2024 Financial Results
BOCA RATON, Fla. --(BUSINESS WIRE)--Mar. 27, 2025-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2024 . |
| 2024-11-12 |
TherapeuticsMD Announces Third Quarter 2024 Financial Results
BOCA RATON, Fla. --(BUSINESS WIRE)--Nov. 12, 2024-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024 . |
| 2024-08-12 |
TherapeuticsMD Announces Second Quarter 2024 Financial Results
BOCA RATON, Fla. --(BUSINESS WIRE)--Aug. 12, 2024-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2024 . |
| 2024-05-10 |
TherapeuticsMD Announces First Quarter 2024 Financial Results
BOCA RATON, Fla. --(BUSINESS WIRE)--May 10, 2024-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024 . |
| 2024-03-29 |
TherapeuticsMD Announces Full Year 2023 Financial Results
• Evaluation of strategic alternatives continues BOCA RATON, Fla. --(BUSINESS WIRE)--Mar. 29, 2024-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, |
Past events
| Date | Event | Type |
|---|---|---|
| 2022-08-15 | TXMD 2022 Q2 Earnings Call | Earnings call |
| 2022-05-16 | TXMD 2022 Q1 Earnings Call | Earnings call |
| 2022-03-10 | TXMD 2021 Q4 Earnings Call | Earnings call |
| 2021-11-11 | TXMD 2021 Q3 Earnings Call | Earnings call |
| 2021-08-04 | TXMD 2021 Q2 Earnings Call | Earnings call |
| 2021-05-06 | TXMD 2021 Q1 Earnings Call | Earnings call |
| 2021-03-09 | H.C. Wainwright Global Life Sciences Conference | Conference |
| 2021-03-03 | Cowen 41st Annual Health Care Conference | Conference |
| 2021-03-02 | TXMD 2020 Q4 Earnings Call | Earnings call |
| 2021-01-11 | H.C. Wainwright Bioconnect 2021 Conference | Conference |
Source: https://ir.therapeuticsmd.com/